comprehensive -WSS

comprehensive

author：fashion 2025-09-28 19:24:59 - browse：838

Has AI really solved biology? What can machines teach us about medicine? And what’s a digital twin?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. It’s our all-AI episode. First, STAT’s Casey Ross joins us to explain his reporting on how researchers and pharmaceutical firms are using the technology to find new drug targets, design therapies, and improve clinical trials. Then, we talk to Joel Dudley, a partner at the venture firm Innovation Endeavors, about how to discern promising ideas from wastes of time when it comes to AI in biotech.

For more on what we cover, here’s the latest on AI in drug development; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Vaccine advisory panel ACIP left half staffed by HHS

WSS

SCOTUS to consider access to abortion pill mifepristone

Spinal cord stimulation reduces pain in amputees, study finds

Radiology is caught between AI's potential and concern for patients

Roche to buy Carmot Therapeutics, developer of obesity drugs

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

In diabetes hearing, Sanders takes on a new foe: food makers

focus

comprehensive

knowledge

At least 13 dead in Texas as scorching temps continue

Congenital heart disease patients face new threat of heart failure

How to save PrEP access — and even expand it

The dental labor crisis is a moment of opportunity

Medical leaders decry Supreme Court decision on affirmative action

Gilead might be held responsible for not developing a drug

Virginia high school admissions case could be legal follow

Key House Republican on health care plans exit from Congress

The cancer drug shortage isn’t new — and neither are the solutions

Why sickle cell disease is getting the first CRISPR treatment

hotspot

Pfizer plans to depart BIO

Private equity deals in Medicare Advantage declines

Pharma patents targeted by Biden in move to slash drug prices

Why did Pfizer dish out millions for a Super Bowl ad?

Pfizer plans to depart BIO

After sickle

leisure time

focus

explore

leisure time